Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Chief Financial Officer | November 03, 2020 | November 04, 2020 |
| Guardant Health, Inc.GH · Entity 3238 | Chief Financial Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date November 03, 2020 · Filed November 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,343 |
Ending reported balance
After 2020-11-03 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2020-11-03 · Exercise / conversion · Acquired 3,333 · Balance 113,610 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 2 · 2020-11-03 · Exercise / conversion · Acquired 12,667 · Balance 126,277 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 3 · 2020-11-03 · Exercise / conversion · Acquired 1,168 · Balance 127,445 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 4 · 2020-11-03 · Exercise / conversion · Acquired 4,167 · Balance 131,612 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 5 · 2020-11-03 · Exercise / conversion · Acquired 3,750 · Balance 135,362 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 6 · 2020-11-03 · Exercise / conversion · Acquired 555 · Balance 135,917 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 7 · 2020-11-03 · Sale · Disposed 32,574 · Balance 103,343 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.00 to $48.85, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2027-04-21 | Direct | 6,667 |
Reported balance
After 2020-11-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-03 · Exercise / conversion · Disposed 3,333 · Balance 6,667 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3: 1/4th of the shares subject to the option vested on April 21, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.17 · Expires 2029-02-04 | Direct | 19,333 |
Reported balance
After 2020-11-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-03 · Exercise / conversion · Disposed 12,667 · Balance 19,333 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4: 1/4th of the shares subject to the option vested on February 4, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.31 · Expires 2028-01-19 | Direct | 4,963 |
Reported balance
After 2020-11-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-03 · Exercise / conversion · Disposed 1,168 · Balance 4,963 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 · Expires 2028-06-29 | Direct | 21,875 |
Reported balance
After 2020-11-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-03 · Exercise / conversion · Disposed 4,167 · Balance 21,875 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2027-10-27 | Direct | 13,125 |
Reported balance
After 2020-11-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-11-03 · Exercise / conversion · Disposed 3,750 · Balance 13,125 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7: 1/4th of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2027-09-01 | Direct | 1,667 |
Reported balance
After 2020-11-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-11-03 · Exercise / conversion · Disposed 555 · Balance 1,667 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8: 50% of the shares subject to the option vested on September 1, 2018 and 1/72nd of the shares subject to the option vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.00 to $48.85, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
F3: 1/4th of the shares subject to the option vested on April 21, 2018 and 1/48th of the shares subject to the option vest monthly thereafter.
F4: 1/4th of the shares subject to the option vested on February 4, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F5: 1/4th of the shares subject to the option vested on January 19, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F6: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F7: 1/4th of the shares subject to the option vested on October 20, 2018 and 1/48th of the shares subject to the option vest monthly thereafter.
F8: 50% of the shares subject to the option vested on September 1, 2018 and 1/72nd of the shares subject to the option vest monthly thereafter.
Guardant Health, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,182 |
Ending reported balance
After 2026-10-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 2,085 · Balance 53,901 Row 2 · 2026-10-01 · Exercise / conversion · Acquired 3,324 · Balance 57,225 Row 3 · 2026-10-01 · Exercise / conversion · Acquired 1,871 · Balance 59,096 Row 4 · 2026-10-01 · Tax withholding · Disposed 3,914 · Balance 55,182 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-01 · Exercise / conversion · Disposed 2,085 · Balance 0 F2: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,296 |
Reported balance
After 2026-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-01 · Exercise / conversion · Disposed 3,324 · Balance 13,296 F4: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,222 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 1,871 · Balance 11,222 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2018 Filed May 13, 2019 20:15 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 12,500 | $1.00 | $12,500.00 |
DisclosureSEC source: 0000899243-19-013218 · doc4a.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment is being filed to report the exercise of an option to purchase 12,500 shares of common stock by the Reporting Person on August 14, 2018 which was inadvertently omitted from the original Form 4. This exercise resulted in an additional 12,500 shares held by the Reporting Person which were inadvertently omitted from the original Form 4 and also were omitted from five Forms 4 filed by the Reporting Person after the date the original Form 4 was filed. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 21:37 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0000899243-18-019280 · doc4.xml · derivative · entry 3 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-29 F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 1, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 21:37 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019280 · doc4.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,738 F2 · shares: The reported securities are represented by restricted stock units, 100% of which were vested upon grant. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 21:37 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019280 · doc4.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,738 F1 · shares: The reported securities are represented by restricted stock units, 1/4th of which shall vest on June 1, 2019 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| June 29, 2018 Filed Jul 12, 2018 23:18 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | Tax withholdingCommon Stock | 8,645 | $12.24 | $105,814.80 |
DisclosureSEC source: 0000899243-18-019824 · doc4a.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,093 F1 · kind: This amendment is being filed solely to report the withholding of shares by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of vested restricted stock units. Read SEC document |
| January 19, 2018 Filed Jan 26, 2018 00:39 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 14,013 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-002020 · doc4.xml · derivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,013 Underlying: Common Stock · 14,013 shares Expires 2028-01-19 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 19, 2019 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2018 Filed Jan 26, 2018 00:39 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 14,013 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002020 · doc4.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,738 F1 · shares: The reported securities are represented by restricted stock units 1/4th of which shall vest on January 19, 2019 and 1/4th of which shall vest on each anniversary thereafter. Read SEC document |
| October 27, 2017 Filed Oct 30, 2017 21:55 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-17-024889 · doc4.xml · derivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-10-27 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on October 20, 2018 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 22:29 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0000899243-17-021471 · doc4.xml · derivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-09-01 F1 · derivative.exercise_date: 50% of the shares subject to the option shall vest on September 1, 2018 and 1/72nd of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 22:21 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseCommon Stock | 350 | $1.84 | $644.98 |
DisclosureSEC source: 0000899243-17-020530 · doc4.xml · nonDerivative · entry 2 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725 Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 22:21 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseCommon Stock | 375 | $1.81 | $679.88 |
DisclosureSEC source: 0000899243-17-020530 · doc4.xml · nonDerivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375 Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 21:22 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0000899243-17-010863 · doc4.xml · derivative · entry 1 Bell Michael Brian · CIK 0001702824 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-04-21 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 21, 2018 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.